Key Takeaways
- Q1 in line, CRO leads: Revenue grew 12% YoY, with the CRO business surging 26% as discovery capacity sold out immediately and a pilot collaboration converted into a long-term partnership.
- FTE model is the structural story: One large pharma engagement expanded end-to-end from discovery to commercial, and management sees this India-first FTE migration as still in early innings with a long runway to scale.
- H2 ramp depends on capacity delivery: CDMO growth was a muted 6% YoY on lumpy purchase-order timing, but two 225 KL production blocks and formulation capability are expected online by late Q2 or early Q3, setting up a stronger second half.
- Peptide and ADC bets are taking concrete shape: A dedicated peptide development lab is live for a top-tier pharma partner, a GMP pilot facility is coming sooner than the 2028 commercial plant, and ADC pilot-scale space is already under construction.
- What to watch next quarter: Whether the two large pharma integrated-model conversions close this year, the pace of the three commercial-supply contract ramp-ups, and any update on the AI initiative promised before year-end.
FTE Model Migration: The Core Structural Shift
- What changed this quarter: A top-tier market-cap pharma FTE engagement expanded into a sizable dedicated contract spanning discovery through commercial manufacturing, and management disclosed it has begun negotiations for another large pharma FTE engagement on the process development side, expected to close by end of Q2 with work commencing Q3.
- Why it matters: The FTE model fills the historical gap in India's CDMO offering between discovery chemistry and late-stage commercial manufacturing, mirroring the path China's large CDMOs took. Management sees these relationships as having potential to expand significantly over the next 5 to 10 years.
- Customer retention logic: Pharma companies' primary stated intent is to leave programs with Sai all the way through the product lifecycle; only a capacity mismatch would cause a move. Sai works with 19 of the top 25 pharma companies and is a preferred vendor, so projects from acquired biotechs often stay or even transfer in.
- Integrated model traction: Already in discussions with several large pharmaceutical companies, with a hope to transition at least two large pharmaceutical customers to integrated models this year.
Krishna Kanumuri: "If you look at the Wuxi model, the customers are engage across discovery, integrated discovery services. Then they're doing all the FTE development services and commercial manufacturing. What India has seen as a first phase is discovery chemistry services and then tech transfer at late-stage commercial manufacturing. But what we are seeing now is the middle part, which is FTE collaboration, with many of these relationships beginning to migrate here."
Capacity Build-Out and the H2 Bet
- Discovery capacity sold out instantly: A new discovery facility that came on stream in Q1 was expected to take a year to a year and a half to fill but is already fully occupied, underscoring demand intensity.
- Bidar production blocks on track: The first of two 225 KL production blocks is on track for H2 or Q3 completion; the second block is also 225 KL. Sai remains on track to reach 1,150 KL total capacity by FY27.
- Formulation entry imminent: Clinical oral solids capability up to Phase 2 is approximately six months away from being operationally ready, driven by customer demand for a China+1 strategy in early-phase clinical materials. This works only with existing development relationships, not as a standalone offering.
- CDMO lumpiness explains the soft Q1: CDMO grew only 6% YoY because the business is inherently lumpy based on delivery and purchase-order timing. Management expects H2 to be stronger than H1 as new capacity comes online by end of Q2 or early Q3.
- Capex discipline: Capacity addition capex is evaluated modularly and just-in-time against internal hurdle rates higher than target ROCE/ROE. Management has a demonstrated history of slowing capex when capacity addition requirements slow down.
Siva Chittor: "There are times in history where even in Sai, where we have demonstrated that when we have seen capacity addition requirements slows down, we slow down the capex. And that is the only way to kind of control and be modular and be as just-in-time as possible as is needed for the business."
New Modalities: Peptides, ADCs, and the Platform Bet
- Peptide development lab live: One dedicated development lab is coming online shortly for a specific top-tier pharma company. A broader GMP pilot facility for clinical supplies is coming online sooner than the 2028 commercial facility.
- Commercial manufacturing timeline: Plan to break ground for a peptide manufacturing facility at a new greenfield site near Hyderabad, expected operational in 2028. Total spend on the peptide side toward end of 2028 is expected to be less than INR 300 crores.
- Strategy breadth, not a GLP-1 chase: Management is building broad-based capabilities across therapeutic windows, citing Merck's PCSK9, J&J's oral peptide for neurology, and peptide-drug conjugates as evidence the modality extends well beyond GLP-1. Capabilities will span discovery, development, and commercial manufacturing.
- ADC footprint under construction: Pilot-scale space for ADCs is already being built, spanning both discovery and development. A broader XDC Center of Excellence is close to opening, supporting synthesis of payloads, linkers, and conjugation across antibodies, peptides, PROTACs, and oligonucleotides.
- New modalities revenue today: 4% to 5% of revenues currently come from new modalities, all on the discovery and development side, not yet commercial.
Krishna Kanumuri: "We are not solely focused on just the GLP-1 space. We are taking a very big position built to support peptides across the therapeutic window. ... we are not just chasing a single modality, we are really building broad-based capabilities in peptides and built a significant technology platform for peptides."
CRO Momentum and Customer Depth
- Discovery growth engine: Discovery revenue has grown at a ~30% to 35% CAGR over the last 4 to 5 years, supported by satellite centers in Boston (established end of 2020) and Manchester that cultivate customers before they need Indian discovery services.
- Pilot-to-partnership conversion: A pilot collaboration with a large pharmaceutical company was converted into a long-term, high-volume discovery chemistry partnership during the quarter.
- Integrated service delivery scaling: Investments in biology and DMPK are now translating into integrated service delivery for ~65% of customers, primarily biotech. A large-scale DMPK data generation project was completed for a biotech customer this quarter.
- Customer retention as a moat: Returning customers accounted for over 90% of revenue in FY25 and FY26. In calendar 2025, Sai contributed to 5 FDA-approved molecules across discovery, development, or commercial manufacturing.
- Biotech funding tailwind: Management expects capital to flow back into funding new biotech companies as investors cash out from ~18 US IPOs and large acquisitions. New companies will be built with even leaner in-house capabilities, supporting healthy demand for outsourced discovery services.
Krishna Kanumuri: "The expectation is for strong scientifically led partners who can take greater ownership of discovery and development programs rather than simply executing individual pieces of work."
Commercial Pipeline and Regulatory Catalysts
- Late-phase funnel: 33 active commercial molecules and 14 molecules in late phase, with 6 late-phase molecules added over the last 15 months, 5 of which came from large pharma clients with ongoing FTE engagements.
- Near-term commercial contracts: Three of four commercial contracts to be worked on this year are commercial supplies, described as decently sized products by value; one is a lower-volume product. Two of the three are probably primary supplier, though management caveated this as anecdotal.
- Regulatory milestones ahead: Two customers have regulatory milestones during FY27; one additional milestone is expected in Q2 of FY28.
- Revenue concentration risk is managed: More than 90% of revenue came from existing customers in FY25 and FY26, reflecting deepening relationships and wallet-share expansion rather than customer concentration fragility.
Guidance, Philosophy, and What Management Declined to Answer
- Mid-term guidance maintained: Management remains confident in sustaining 15% to 20% revenue growth and 28% to 30% EBITDA margins over a three-to-five-year period, with an explicit philosophy to "meet and beat" the guidance given to the market.
- H2 > H1 conviction: The second half of FY27 is expected to be stronger than the first half, driven by capacity coming on stream by end of Q2 or early Q3.
- AI initiative update pending: Current focus is on eliminating non-value-add wastage such as document generation, data extraction from scientific literature, and online help for chemists and operators. An update is expected before the end of the year. High-throughput experimentation is a separate initiative.
- What management would not quantify: Customer-specific revenue potential for the converted large pharma relationship, revenue per product for the four commercial contracts, therapeutic-wise revenue split for the quarter, FY28 capex guidance, late-stage molecule revenue potential and completion timelines, peptide project and customer counts, and any details on mAb or fermentation strategy.
Siva Chittor: "Have I put all my bets on it and every last dollar to get the 15%-20%? Obviously, we would also want to kind of make sure we will meet and beat guidance that we give to the market."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% to 20% over a three-to-five-year period | Mid-term (3–5 years) |
| EBITDA margin | 28% to 30% range | Mid-term (3–5 years) |
| H2 stronger than H1 | Driven by capacity coming online | End of Q2 or early Q3 FY27 |
| Capacity target | Reach 1,150 KL total capacity | By FY27 |
| Bidar production block 1 | 225 KL block completion | H2 or Q3 FY27 |
| Formulation capability | Clinical oral solids up to Phase 2 operational | Approximately six months (~Q3/Q4 FY27) |
| Peptide commercial facility | Ground-breaking at greenfield site near Hyderabad; operational | 2028 |
| Peptide total spend | Less than INR 300 crores | Toward end of 2028 |
| Large pharma FTE engagement (new) | Negotiations to close; work to commence | Close by end of Q2 FY27; work from Q3 FY27 |
| Integrated model conversions | Transition at least two large pharma customers to integrated models | FY27 |
| Regulatory milestones | Two customer milestones | FY27 |
| Regulatory milestone (additional) | One customer milestone | Q2 FY28 |
| AI initiative update | Update on AI-driven productivity initiatives | Before end of FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹553 cr, +12% YoY vs ₹496 cr in Q1 FY26 |
| CDMO revenue share | ~60% of total revenue |
| CRO revenue share | ~40% of total revenue |
| CRO revenue growth | ~26% YoY |
| CDMO revenue growth | ~6% YoY |
| Active commercial molecules | 33 |
| Late-phase molecules | 14 |
| Late-phase molecules added (last 15 months) | 6, of which 5 came through large pharma FTE engagements |
| Returning customer revenue share | Over 90% in FY25 and FY26 |
| FDA-approved molecules contributed to (CY2025) | 5 |
| Launches supported (past 5 years) | 17 |
| Revenue growth guidance (mid-term) | 15% to 20% over a three-to-five-year period |
| EBITDA margin guidance | 28% to 30% |
| FY27 capex guidance | ₹1,100 cr to ₹1,300 cr |
| Capacity target | 1,150 KL by FY27 |